Retrospective web-based multicenter evaluation of ¹⁸F-FDG-PET and CT derived predictive factors. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan in follicular non Hodgkin's lymphoma
- PMID: 21057722
- DOI: 10.3413/nukmed-0322-10-06
Retrospective web-based multicenter evaluation of ¹⁸F-FDG-PET and CT derived predictive factors. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan in follicular non Hodgkin's lymphoma
Abstract
Aim: Although predictive factors (PF) for conventional lymphoma therapy are established and frequently used in clinical practice and medical research, the PF for radioimmunotherapy (RIT) have not been fully defined until now. The aim of this multicenter evaluation is to prove the feasibility of the multicenter web-based data collection and to preliminary explore imaging findings and prediction of therapy response in patients with follicular lymphoma (FL) following radioimmunotherapy (RIT) with 90Y-ibritumomab tiuxetan.
Patients, methods: We retrospectively analyzed and correlated clinical and imaging data (CT and FDG-PET) before and after RIT as documented by the RIT-Network. Evaluation of treatment response was done on both patient and lesion basis. Every measurable lesion was analyzed in terms of standardized uptake value (SUV), volume (CT and PET) and response. PF were identified using a uni- and multivariate model. A web-based system was used for the documentation and evaluation of clinical and imaging data.
Results: 16 patients with at least one PET before and after RIT were eligible for analysis. Concerning response three months postRIT, 5 patients achieved a CR, 6 patients a PR and 4 patients remained with NC. A total of 159 lesions were measured (mean 10±8). In the multivariate model the log lesion volume (p < 0.0001), the total (p = 0.03) and maximum lesion volume (p = 0.05) were predictors for response (CR + PR). Concerning the lesional CR initial small lesion volume (p = 0.009) and its high metabolic activity (p = 0.01) were identified as predictors. The web-based system showed no major disturbances allowing secure data transfer and central image interpretation in a reasonable time.
Conclusion: The use of a web-based multicenter archiving system for clinical and imaging data is technically feasible in a multicenter setting and allows a central analysis. This preliminary analysis suggests that FDG-PET may predict the likelihood of response to RIT.
Similar articles
-
FDG PET and 90Y ibritumomab tiuxetan in patients with follicular lymphoma.Q J Nucl Med Mol Imaging. 2010 Aug;54(4):436-41. Epub 2010 May 27. Q J Nucl Med Mol Imaging. 2010. PMID: 20823812
-
FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study.Ann Oncol. 2010 Sep;21(9):1877-1883. doi: 10.1093/annonc/mdq024. Epub 2010 Feb 10. Ann Oncol. 2010. PMID: 20147744
-
Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.Radiology. 2010 Jan;254(1):245-52. doi: 10.1148/radiol.09090603. Radiology. 2010. PMID: 20032155
-
Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop.Eur J Cancer. 2008 Feb;44(3):366-73. doi: 10.1016/j.ejca.2007.12.008. Epub 2008 Jan 14. Eur J Cancer. 2008. PMID: 18194857
-
Radioimmunotherapy for non-Hodgkin's lymphoma: a review for radiation oncologists.Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):833-41. doi: 10.1016/j.ijrobp.2006.05.030. Epub 2006 Sep 11. Int J Radiat Oncol Biol Phys. 2006. PMID: 16965871 Review.
Cited by
-
Early evaluation of tumor response to 90Y-ibritumomab radioimmunotherapy in relapsed/refractory B cell non-Hodgkin lymphoma: what is the optimal timing for FDG-PET/CT?Eur Radiol. 2019 Jul;29(7):3935-3944. doi: 10.1007/s00330-019-06134-7. Epub 2019 Mar 21. Eur Radiol. 2019. PMID: 30899979
-
The Empirical Foundations of Teleradiology and Related Applications: A Review of the Evidence.Telemed J E Health. 2016 Nov;22(11):868-898. doi: 10.1089/tmj.2016.0149. Epub 2016 Sep 1. Telemed J E Health. 2016. PMID: 27585301 Free PMC article. Review.
-
Heterogeneity of intratumoral (111)In-ibritumomab tiuxetan and (18)F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin's lymphoma.EJNMMI Res. 2015 Mar 14;5:10. doi: 10.1186/s13550-015-0093-3. eCollection 2015. EJNMMI Res. 2015. PMID: 25853016 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials